North Carolina researcher receives award for new ant-HIV drug that simplifies treatment regime

December 03, 2000

Susan Daluge of Chapel Hill, North Carolina, will be honored on December 8 by the world's largest scientific society for her contributions to the development of a new anti-HIV drug that can dramatically simplify treatment. She will receive one of four 2000 Industrial Innovation Awards at the American Chemical Society's Southeast-Southwest Combined Regional Meeting in New Orleans.

Ziagen® increases the anti-viral potency of AZT and 3TC, two traditional anti-HIV drugs. It is particularly useful for patients who cannot tolerate so-called protease inhibitors - another class of highly effective anti-HIV drugs - because they experience side effects.

Ziagen® in combination with AZT and 3TC provides a safe, effective alternative. Moreover, the three drugs can be combined in a single pill (Trizivir) that is taken twice daily instead of as 10 to 20 separate pills.

"Ziagen® is the first carbocyclic nucleoside to be approved as a drug," says Daluge, noting that many other compounds in the same class have been studied for more than 30 years by anti-viral and anti-cancer researchers.

As a researcher at Glaxo Wellcome Inc., Daluge has been working on Ziagen® since 1988. She led the group of scientists whose early work lead to the selection of Ziagen® for clinical trials. After it proved effective in 1995, a way had to be found to synthesize it on a large enough scale to make it available to patients. Daluge came up with an approach the U.S. Food and Drug Administration approved in late 1998.

Through its industrial innovation awards program, the American Chemical Society recognizes individuals and teams whose discoveries and inventions contribute to the commercial success of their companies and enhance the quality of life.
-end-


American Chemical Society

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.